Morepen Laboratories Limited has informed the Exchange about General Updates
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Morepen Laboratories, at its meeting on August 6, 2025, approved the unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). On a consolidated basis, total income fell to Rs. 42,964.73 lakhs from Rs. 45,864.27 lakhs in Q1 FY25, and net profit (after minority interest) dropped sharply to Rs. 1,074.83 lakhs from Rs. 3,616.79 lakhs a year ago, with EPS at Rs. 0.20 versus Rs. 0.71. On a standalone basis, net profit fell to Rs. 806.12 lakhs (EPS Rs. 0.15) from Rs. 3,504.96 lakhs (EPS Rs. 0.69). A major reason for the profit decline is that the company's stake in Dr. Morepen Limited fell from 80% to 19.94% (via a Rs. 30.65 crore share sale and a fresh issue for the GTPL acquisition), so DML has ceased to be a subsidiary. The Board fixed August 30, 2025 as the record date for the proposed final dividend (subject to AGM approval), and called the 40th AGM for September 6, 2025 via video conferencing. It also approved seeking shareholder approval to extend the timeline for hiving off the Medical Devices business into Morepen Medipath Limited on a slump sale basis, re-appointment of Mr. Sanjay Suri (brother of CMD Mr. Sushil Suri) as Whole-Time Director for three more years (Aug 13, 2025 – Aug 12, 2028), and appointment of M/s. PD and Associates as Secretarial Auditor for five years (FY26–FY30).
The sharp YoY fall in profits – driven largely by the deconsolidation of Dr. Morepen Limited and higher depreciation and finance costs – is a clear negative for headline earnings, though it reflects a structural change rather than an operational collapse. Shareholders still on the record as of August 30, 2025 will be eligible for the final dividend, and AGM approvals on the director re-appointment, hive-off extension, and new auditor are procedural. Watch for the demerged Medical Devices business performance and the standalone trajectory, since consolidated numbers will no longer fully capture the OTC/consumer health play previously housed in DML.